The F.D.A. typically issues its decisions within a few days of advisory committee meetings, during which members discuss safety and efficacy data. The timing of the upcoming meetings indicates that the agency intends to move quickly to decide whether to authorize both the booster and children’s shots.
The committee will meet on Oct. 14 and 15 to discuss booster doses, and is tentatively scheduled to discuss Pfizer’s pediatric vaccine on Oct. 26, the agency said…
The decision to have the committee discuss the evidence for Moderna and Johnson & Johnson booster shots two weeks before it does so for Pfizer’s children’s vaccine appears to reflect the F.D.A.’s priorities and the availability of data. But the agency’s decisions on those emergency use authorizations could come in quick succession.
Join the conversation as a VIP Member